

Shoulder Chondrolysis Can Be a Complication of Arthroscopy

BY BRUCE JANCIN

KEYSTONE, COLO. — Iatrogenic chondrolysis in young athletes has emerged in the past several years as a devastating complication of shoulder arthroscopy, shoulder specialists said at the annual meeting of the American Orthopaedic Society for Sports Medicine.

“We’ve learned over the last year or two that our routine treatments don’t work in patients with chondrolysis. These people hurt no matter what you do, even if you do a full-on total shoulder replacement,” according to Dr. David S. Bailie, a Scottsdale, Ariz., orthopedic surgeon.

Chondrolysis is the disappearance of articular cartilage through dissolution of the cartilage matrix and cells. Affected patients typically complain of a rapid increase and change in the nature of their shoulder pain occurring roughly 8-12 months after arthroscopic surgery. X-rays show a clear loss of joint space soon after the procedure. A true anteroposterior view of the glenoid, along with axillary views, is the most helpful image for diagnosing the condition.

“Think of chondrolysis as a chemical burn, like dipping something in acid. It’s not really arthritis,” Dr. Bailie explained. “Arthroscopy is not a good choice in chondrolysis for the simple reason that there aren’t any loose bodies to remove. There isn’t any cartilage left.”

Circumstantial evidence has linked chondrolysis to arthroscopic procedures involving mishandling of thermal probes, the use of bioabsorbable labral fixation devices containing proinflammatory compounds such as polyglycolic acid, and—most significantly—postoperative use of high-volume intra-articular pain pumps to administer local anesthetic.

“This is our biggest nemesis now: pain pumps. Unfortunately, people all over the country are still using them. We’re just starting to learn that this medicine we’ve used for half a century—local anesthetic—is extremely toxic to all human tissue,” Dr. Bailie said.

He considers surgery when chondrolysis patients don’t improve substantially after 3 months of conservative treatment such as NSAIDs, physical therapy, an intra-articular steroid injection, or intra-articular hyaluronic acid.

The best operation in these patients is often a stemmed arthroplasty, in some cases with a lateral meniscus allograft transplant on the glenoid.

“We’ve found out the hard way that resurfacing procedures don’t work most of the time in chondrolysis. It probably has to do with the neural elements in the subchondral bone being affected. The chemical burn you get with chondrolysis often goes deeper than the articular cartilage.

“That’s why I always get a planning MRI: If patients have any cystic changes in the bone, they have to have a stemmed arthroplasty—you have to cut the humeral

head off. If they don’t have any cystic changes, we’ve had some success with resurfacing; but most of the time they look like rheumatoid arthritis patients, with cysts on both sides of the joint,” he said.

Todd Ellenbecker, a Scottsdale, Ariz., physical therapist with a quarter-century of experience, said

one of the greatest challenges in his daily clinical practice is restoring scapular stabilization and rotator cuff strength in chondrolysis patients following arthroplasty.

He advocates passive and active assisted range-of-motion exercises aimed at establishing scapular stabilization. ■



The loss of articular cartilage (as above, around the humeral head) can occur after arthroscopy.


PHOTO COURTESY DR. DAVID BAILIE OF THE ORTHOPAEDIC CLINICAL ASSOCIATION, SCOTTSDALE, AZ

FOR THE TOPICAL TREATMENT OF ACUTE PAIN DUE TO MINOR STRAINS, SPRAINS, AND CONTUSIONS

NSAID POWER

that targets the site of acute pain






- Dispensed in boxes of 30 patches
 - 2 weeks of therapy = 1 box
 - 1 month of therapy = 2 boxes

FLECTOR® Patch

- A unique way of delivering the proven efficacy of the nonsteroidal anti-inflammatory drug, diclofenac, in a patch
- Substantially lower (<1%) systemic exposure and maximum plasma concentrations of diclofenac with FLECTOR® Patch vs 1 dose of a 50-mg oral diclofenac sodium tablet



FLECTOR® Patch (diclofenac epolamine topical patch) 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.

Carefully consider the potential benefits and risks of FLECTOR® Patch and other treatment options before deciding to use FLECTOR® Patch. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.

Important Safety Information

Cardiovascular (CV) risk

- NSAIDs may cause an increased risk of serious CV thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with CV disease or risk factors for CV disease may be at greater risk
- FLECTOR® Patch is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft surgery

Gastrointestinal (GI) risk

- NSAIDs cause an increased risk of serious GI adverse events at any time during use and without warning symptoms including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients are at greater risk of serious GI events

FLECTOR® Patch is contraindicated in patients with known hypersensitivity to diclofenac. FLECTOR® Patch should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.

FLECTOR® Patch should not be applied to nonintact or damaged skin resulting from any etiology, eg, exudative dermatitis, eczema, infected lesion, burns, or wounds.

NSAIDs, including FLECTOR® Patch, can lead to new onset or worsening of hypertension, contributing to increased incidence of CV events. Fluid retention and edema have been observed in some patients taking NSAIDs. Use with caution in patients with hypertension, fluid retention, or heart failure.

A patient with symptoms and/or signs of liver dysfunction, or with a history of an abnormal liver test, should be monitored for a more severe hepatic reaction and therapy stopped. Anemia is sometimes seen in patients receiving NSAIDs, and platelet inhibition has been shown to prolong bleeding times.

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in maintaining renal perfusion. FLECTOR® Patch is not recommended in patients with advanced renal disease.

NSAIDs, including FLECTOR® Patch, can cause serious skin adverse events without warning such as exfoliative dermatitis, Stevens-Johnson Syndrome, and toxic epidermal necrolysis, which can be fatal. Patients should be informed about the signs and symptoms of serious skin manifestations, and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.

Overall, the most common adverse events associated with FLECTOR® Patch were skin reactions (pruritus, dermatitis, burning, etc) at the site of treatment, GI disorders (nausea, dysgeusia, dyspepsia, etc), and nervous system disorders (headache, paresthesia, somnolence, etc).


In late pregnancy, as with other NSAIDs, FLECTOR® Patch should be avoided because it may cause premature closure of the ductus arteriosus. FLECTOR® Patch is in Pregnancy Category C. Safety and effectiveness in pediatric patients have not been established.

Please see Brief Summary of full Prescribing Information, including boxed warning, on the following page.

Healthcare Professional: Please provide a Medication Guide to each patient.

For more information, please visit www.FlectorPatch.com or www.KingPharm.com.

Reference: Flector Patch [package insert]. Piscataway, NJ: Alpharma Pharmaceuticals LLC; 2009.



Flector® patch

(diclofenac epolamine topical patch) 1.3%
Targeted NSAID Power

FLECTOR is a registered trademark of IBSA Institut Biochimique SA. Copyright © 2009 King Pharmaceuticals, Inc. All rights reserved. FLE6410 07/2009